SCHEMBL7047488

SCHEMBL7047488

CC(CO)Nc1ccc(S(=O)(=O)Oc2ccc3[nH]c(NC(=O)NCCN4CCOCC4)nc3c2)cc1.CCNC(=O)Nc1nc2cc(OS(=O)(=O)c3ccc(NCCOC)cc3)ccc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.43
CDK9 P50750 1/20 0.43
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.35
MAPK1 P28482 1/20 0.35
PIK3CA P42336 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
LMNA P02545 1/20 0.35
NPC1 O15118 1/20 0.34
HPGD P15428 1/20 0.34
SYK P43405 1/20 0.34
ABL1 P00519 1/20 0.34
SCN9A Q15858 1/20 0.34
AURKB Q96GD4 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5040941 0.92 ALDH1A1 (0.41) METCDK9ALDH1A1KDM4EMAPT
SCHEMBL5139529 0.91 MET (0.51) METCDK9ALDH1A1KDM4EMAPT
SCHEMBL5036224 0.89 MET (0.52) METCDK9ALDH1A1KDM4EMAPT
SCHEMBL5036240 0.85 MET (0.55) METCDK9ALDH1A1KDM4EMAPT
SCHEMBL5042998 0.84 ABL1 (0.44) METCDK9ABL1
SCHEMBL5036031 0.84 MET (0.56) METCDK9ABL1
SCHEMBL5040962 0.81 TSHR (0.45) METCDK9ALDH1A1KDM4EMAPT
SCHEMBL5036010 0.81 MET (0.62) METCDK9ALDH1A1KDM4EMAPT
SCHEMBL5036221 0.81 SMN1; SMN2 (0.40) METCDK9ALDH1A1KDM4EMAPT
SCHEMBL5036524 0.80 AURKB (0.43) METCDK9ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432417-A2 SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER Aventis Pharma S.A. (FR) 2004-06-30 EP disclosed
WO-2003028721-A2 SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER AVENTIS PHARMA S.A. (FR) 2003-04-10 WO disclosed